| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20047210 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS44015624 | HTLV-1 | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS44043967 | HTLV-1 | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR1D |
|---|---|
| DrugBank ID | DB00998 |
| Drug Name | Frovatriptan |
| Target ID | BE0000659 |
| UniProt ID | P28221 |
| Regulation Type | agonist |
| PubMed IDs | 11752352; 11735616; 12028320; 11152011; 10883409; 15185063; 15311727; 9700983; 18360605; 15342617; 12028322 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Easthope SE, Goa KL: Frovatriptan. CNS Drugs. 2001;15(12):969-76; discussion 977-8.@@Comer MB: Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache. 2002 Apr;42 Suppl 2:S47-53.@@Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87.@@Deleu D, Hanssens Y: Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol. 2000 Jul;40(7):687-700.@@Jahnichen S, Radtke OA, Pertz HH: Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):54-63. Epub 2004 Jun 8.@@Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract. 2004 Jul;58(7):695-705.@@Parsons AA, Raval P, Smith S, Tilford N, King FD, Kaumann AJ, Hunter J: Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998 Aug;32(2):220-4.@@Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8.@@Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Oct;44(10):1158-65.@@Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S: Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73. |
| Groups | Approved; Investigational |
| Direct Classification | Carbazoles |
| SMILES | CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O |
| Pathways | |
| PharmGKB | PA164754891 |
| ChEMBL | CHEMBL1279 |
